AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00396409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depigoid
Description: Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
Study NCT00396409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: anti-IgE (Omalizumab) given during the 2006 core study
Study NCT00396409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo given during the 2006 core study
Study NCT05971615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peripheral venous blood gases
Description: peripheral venous blood gases
Study NCT01878955 — intervention group
Intervention type: GENETIC
Intervention: AMH level difference between patient with PCOS and multicystic ovaries.
Study NCT02854709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Sleep extension by 1 hour for 2 weeks
Study NCT04564222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Enriched Crackers (MECs)
Description: MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product.
Study NCT04564222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product.
Study NCT03131271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
Study NCT04898686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic chewables
Description: chewables containing Lacticaseibacillus rhamnosus GG
Study NCT04898686 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chewables
Description: chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
Study NCT03352674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine Ezelin
Description: Insulin Glargine (Ezelin) once daily at individually adjusted dose
Study NCT03352674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine Pen Injector [Lantus]
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Study NCT02892630 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03402295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
Description: Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
Study NCT00115076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: 24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
Study NCT02904772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: alipogene tiparvovec
Description: A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
Study NCT02904772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: IV bolus methylprednisolone 1mg/kg half hour prior to administration
Study NCT02904772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporins
Description: Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
Study NCT02904772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil
Description: Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
Study NCT02487914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)
Description: drug delivery through interferential current.
Study NCT02487914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 10% was sprayed at the identified region
Study NCT02487914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Study NCT01615367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition, Exercise, and Wellness (NEW) psychotherapy
Description: NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
Study NCT01615367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typically consists of at least one FDA-approved mood stabilizer
Description: Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
Study NCT01416519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) facial mask
Description: After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
Study NCT01416519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted deep inspiration technique
Description: After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
Study NCT02597764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Study NCT02597764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urotherapy
Study NCT02597764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Urotherapy
Study NCT02623725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine (5-dose formulation)
Description: 0.5 mL, Subcutaneous
Study NCT02623725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo, NaCl 0.9%
Description: 0.5 mL, Subcutaneous
Study NCT01864707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care + acupuncture
Description: Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
Study NCT01864707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care+mbsr
Description: Patients of this group receive mindfulness based stress reduction in addition to usual care
Study NCT01864707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Patients in this group will follow the same treatment for fatigue they received at study entry
Study NCT02509429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol
Study NCT02509429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend
Description: The insuline used is usual patient insuline. There is no specific insulin for this protocol
Study NCT03347682 — intervention group
Intervention type: OTHER
Intervention: Satisfaction with Prosthesis -SATPRO
Description: questionnaire 1
Study NCT03347682 — intervention group
Intervention type: OTHER
Intervention: Nottingham Health Profile-NHP
Description: questionnaire 2
Study NCT03347682 — intervention group
Intervention type: OTHER
Intervention: Prosthesis donning and doffing questionnaire
Description: questionnaire 3
Study NCT00676702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus
Description: A high-fat liquid meal of 500 ml of Ensure Plus
Study NCT00676702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase in combination with Ensure Plus
Description: 3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
Study NCT00941915 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT Prostate
Description: Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
Study NCT01776034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE Group Lifestyle counseling
Study NCT01776034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Lifestyle Counseling
Study NCT01721226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Arm (computer-based CARE+ Corrections tool)
Description: Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
Study NCT01721226 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Educational video on opiate overdose prevention
Description: Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
Study NCT03058926 — intervention group
Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
Study NCT01424501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: Intramuscular injection, 2 doses
Study NCT01424501 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 2 doses
Study NCT03530267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept + mLV5FU2
Description: Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
Study NCT03530267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX7
Description: Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared with non fluoridated water
Description: Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared with fluoridated water
Description: Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non fluoridated water
Description: Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoridated water
Description: Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared to provide a fluoride dose of 60 ug F/kg
Description: Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
Study NCT01978041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal prepared to provide a fluoride dose of 120 ug F/kg
Description: Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
Study NCT02202343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: school based health and nutrition education
Study NCT00724984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I.
Study NCT01212393 — intervention group
Intervention type: BEHAVIORAL
Intervention: reminders
Description: In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
Study NCT01361100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oncoral® test
Description: The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
Study NCT00660179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan (ACT-064992)
Description: Tablet, 3 mg dosage, once daily
Study NCT00660179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan (ACT-064992)
Description: Tablet, 10 mg dosage, once daily
Study NCT00660179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo, once daily
Study NCT03432169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga (stretching plus mindfulness)
Description: Stretching plus mindfulness
Study NCT03432169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching alone
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide spray
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide spray
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide cream
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide cream
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol spray
Study NCT01736670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol spray
Study NCT00852787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin immune fab
Description: Intravenously one time
Study NCT04951869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protescal gel
Description: Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
Study NCT00852787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously one time
Study NCT02032498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
Study NCT02289807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
Study NCT02289807 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
Study NCT02289807 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
Study NCT00636285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00636285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSYX-A110
Description: BSYX-A110, Dosed intravenously, 3 mg/kg
Study NCT00636285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSYX-A110
Description: BSYX-A110, Dosed intravenously, 10 mg/kg
Study NCT00853151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: 14 mg subcutaneous injection 1 time a week for 5 weeks
Study NCT04595825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101)
Description: Anti-human CCL24 monoclonal antibody (CM-101) 100 mg Intravenous Infusion over 60 minutes (±5 minutes)
Study NCT00853151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT223
Description: subcutaneous injection once a day for 4 weeks
Study NCT00853151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LY2428757
Description: subcutaneous injection 1 time a week for 5 weeks
Study NCT00853151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for TT223
Description: subcutaneous injection once a day for 4 weeks
Study NCT00853151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TT223
Description: subcutaneous injection once a day for 4 weeks
Study NCT00291018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement
Description: Total Disc Replacement using ProDisc-C
Study NCT00291018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF
Description: Anterior Cervical Discectomy and Fusion
Study NCT01800630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine HCl Oral Formulation
Study NCT01504412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: Oral tablets administered twice daily